Pefloxacin kinetics in cirrhosis

Area of Science:

• Pharmacology
• Hepatology

Background:

• Cirrhosis of the liver significantly alters drug pharmacokinetics.
• Understanding pefloxacin's behavior in cirrhosis is crucial for patient safety.

Purpose of the Study:

• To evaluate pefloxacin pharmacokinetics in patients with liver cirrhosis.
• To compare these pharmacokinetics with those in healthy individuals.

Main Methods:

• Pharmacokinetic analysis of pefloxacin in 16 cirrhosis patients and 12 healthy subjects.
• Measurement of drug half-life (t1/2), volume of distribution, and plasma clearance.
• Analysis of urinary excretion of pefloxacin and its metabolite N-desmethyl pefloxacin.

Main Results:

• Pefloxacin's half-life was significantly longer in cirrhosis patients (35.10 hrs) vs. healthy subjects (11.00 hrs).
• Volume of distribution decreased by 18% and total plasma clearance was markedly reduced in patients.
• Higher unchanged pefloxacin and lower N-desmethyl pefloxacin excretion observed in patients.

Conclusions:

• Decreased hepatic metabolism likely causes reduced pefloxacin clearance in cirrhosis.
• Pefloxacin dosage adjustments are recommended for patients with liver cirrhosis.
• Cirrhosis complications like ascites and jaundice further prolong drug half-life.